{
    "clinical_study": {
        "@rank": "109192", 
        "arm_group": [
            {
                "arm_group_label": "PPP", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo: Platelet Poor Plasma\nUnder sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).\nFollowing the completion of the injections (treatment or control) physiotherapy will commence.  Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
            }, 
            {
                "arm_group_label": "PRP", 
                "arm_group_type": "Active Comparator", 
                "description": "Biological: Platelet Rich Plasma\nUnder sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).\nFollowing the completion of the injections (treatment or control) physiotherapy will commence.  Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
            }, 
            {
                "arm_group_label": "Physiotherapy", 
                "arm_group_type": "No Intervention", 
                "description": "These patients will not receive an injection.\nFollowing the inclusion physiotherapy will commence.  Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the therapeutic benefit of utilizing complex growth\n      factor preparations (Platelet Rich Plasma (PRP) in the management of acute hamstring\n      injuries.\n\n      The hypothesis is that the time to return to sport is shorter in the patient group treated\n      with Complex Growth Factor Preparations (PRP) in combination with exercise therapy in\n      comparison with 2 control groups:\n\n        -  the patient group treated with Platelet Poor Plasma (PPP) injections in combination\n           with exercise therapy (control injection AND usual care).\n\n        -  the patient group treated with exercise therapy (usual care)"
        }, 
        "brief_title": "Use of Platelet Rich Plasma in the Management of Acute Hamstring Muscle Strain Injury", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Hamstring Muscle Strain Injury", 
        "condition_browse": {
            "mesh_term": [
                "Sprains and Strains", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute onset posterior thigh pain\n\n          -  MRI confirmed Grade I, II hamstring lesions\n\n          -  < 5 days from injury\n\n          -  Able to perform Physiotherapy at ASPETAR (5 sessions/week)\n\n          -  Available for follow-up\n\n          -  Male\n\n          -  Age > 18 years\n\n        Exclusion Criteria:\n\n          -  Diabetes, immuno-compromised state\n\n          -  Overlying skin infection\n\n          -  Re-injury or Chronic ongoing hamstring injury\n\n          -  Unwilling to comply with follow up\n\n          -  Contraindication to MRI\n\n          -  Needle Phobia\n\n          -  Bleeding disorder or other medical contraindication to injection\n\n          -  Medication increasing bleeding risk (e.g. Plavix)\n\n          -  Concurrent other injury inhibiting rehabilitation"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812564", 
            "org_study_id": "GF012"
        }, 
        "intervention": [
            {
                "arm_group_label": "PPP", 
                "intervention_name": "Platelet Poor Plasma (PPP)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PRP", 
                "intervention_name": "Platelet Rich Plasma (PRP)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Platelet rich plasma", 
            "Interventional", 
            "Randomized", 
            "Double-blind"
        ], 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Doha", 
                    "country": "Qatar", 
                    "zip": "29222"
                }, 
                "name": "Aspetar; Qatar Orthopaedic and Sports Medicine Hospital"
            }
        }, 
        "location_countries": {
            "country": "Qatar"
        }, 
        "number_of_arms": "3", 
        "official_title": "Clinical Utilization of Growth Factors Preparations in the Management of Acute Hamstring Muscle Strain Injury", 
        "other_outcome": [
            {
                "measure": "Pain during walking, jogging, running, sprinting, acceleration and during training.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Pain with isometric contraction against resistance assessed with the visual analogue scale(VAS).", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Length and width of pain area during palpation and location of pain on palpation.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Passive straight leg raising test.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Full knee extension test at rest.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "90 degrees hip flexion test.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "(Painful) resisted knee flexion test at 90 degrees.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Pain with resisted hip extension test at 30 degrees.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Slump test.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play. (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "MRI scoring.", 
                "safety_issue": "No", 
                "time_frame": "3 weeks after date of injury."
            }, 
            {
                "measure": "Hamstring strength", 
                "safety_issue": "No", 
                "time_frame": "At time of return to play (The expected average return to play time is 27 days)"
            }, 
            {
                "measure": "Adverse effects.", 
                "safety_issue": "No", 
                "time_frame": "Once every 7 days from the inclusion date until the time to return to play (the expected average return to play time is 27 days), 2 months after return to play, at the end of the sport season, and at 1 year after return to play."
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Aspetar", 
                "last_name": "Hakim Chalabi, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Aspetar", 
                "last_name": "Bruce Hamilton, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Qatar: Council of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to return to full sports activity; either training or match play.", 
            "measure": "Time to Return to Play", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of time to return to play with an expected average of 27 days and up to 1 year."
        }, 
        "reference": [
            {
                "PMID": "22144005", 
                "citation": "Ekstrand J, Healy JC, Wald\u00e9n M, Lee JC, English B, H\u00e4gglund M. Hamstring muscle injuries in professional football: the correlation of MRI findings with return to play. Br J Sports Med. 2012 Feb;46(2):112-7. doi: 10.1136/bjsports-2011-090155. Epub 2011 Dec 5."
            }, 
            {
                "PMID": "20068208", 
                "citation": "de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, Tol JL. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010 Jan 13;303(2):144-9. doi: 10.1001/jama.2009.1986."
            }, 
            {
                "PMID": "21200168", 
                "citation": "Hamilton BH, Best TM. Platelet-enriched plasma and muscle strain injuries: challenges imposed by the burden of proof. Clin J Sport Med. 2011 Jan;21(1):31-6. doi: 10.1097/JSM.0b013e318205a658. Review."
            }, 
            {
                "PMID": "20973348", 
                "citation": "Hamilton B, Knez W, Eirale C, Chalabi H. Platelet enriched plasma for acute muscle injury. Acta Orthop Belg. 2010 Aug;76(4):443-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Recurrent hamstring lesions.", 
            "safety_issue": "No", 
            "time_frame": "2 months after return to play, 1 year after return to play."
        }, 
        "source": "Aspetar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aspetar", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}